I-Mab Unveils Strategic Changes, Hong Kong IPO Plans, and Rebrands to NovaBridge Biosciences

I-Mab, a global biotechnology platform company, announced a shift in strategy to focus on business development and translational clinical development aimed at getting innovative medicines to patients quickly. The company shared its intent to conduct an initial public offering (IPO) in Hong Kong, aiming to increase access to global capital through listings on both NASDAQ and the Hong Kong Stock Exchange. A new name, NovaBridge Biosciences, will be adopted pending shareholder approval at an Extraordinary General Meeting on October 24, 2025. The pending acquisition of a novel biologic compound known as VIS-101, set to enhance treatment for wet AMD and…